London, United Kingdom (PressExposure) December 09, 2009 -- Cardiac Resynchronization Therapy (CRT) devices have been studied clinically since 1998, and have been on the US market since the FDA approval of the first product in 2001.
CRT (also known as biventricular pacing) is used for the prevention and treatment of congestive heart failure caused by dilated cardiomyopathy. CRT devices typically have three leads implanted into one atrium and two ventricles of the heart. The wires that carry the electrical signals in a pacemaker connect to an electrical pulse generator placed under the skin in the upper chest. In addition to the two leads (right atrium and right ventricle) used by a common pacemaker, the CRT device has a third lead that is positioned in a vein on the surface of the left ventricle. This system allows the CRT device to simultaneously stimulate the left and right ventricles and restore a coordinated or âsynchronousâ heart beat pattern. This is also referred to as âbi-ventricular pacingâ because both ventricles are electrically paced at the same time.
This analysis was taken from a research paper published by GlobalData, to download the full Research Paper for free, click below:
Access the latest Cardiovascular Devices analysis for free at http://www.researchviews.com
ResearchViews is your number one portal for industry related news, research, analysis and deals data. ResearchViews offers up to the minute content produced by an expert team of industry analysts.
All content on the site is free to view and allows users to keep up to date with the latest developments in their chosen industry. Free daily and weekly newsletters provide a snapshot of the major issues affecting the industry. The site also features a research store, providing the user with access to premium business intelligence from some of the world's leading market research publishers.